What Alzheimer’s projects has Bill Gates funded through the Gates Foundation since 2020?

Checked on December 17, 2025
Disclaimer: Factually can make mistakes. Please verify important information or breaking news. Learn more.

This fact-check may be outdated. Consider refreshing it to get the most current information.

Executive summary

Since 2020 Bill Gates has been visible as a funder and convenor in Alzheimer’s research—backing data-sharing and diagnostics initiatives, underwriting targeted clinical-trial grant programs, and supporting AI and venture-style investments—but public reporting and the available documents do not provide a single, definitive ledger of “Gates Foundation” grants limited to 2020–present, and several of Gates’s contributions have been made personally or through affiliated entities rather than explicitly from the Bill & Melinda Gates Foundation [1] [2] [3].

1. Data, platforms and a convening role: the Alzheimer’s Disease Data Initiative (ADDI) and related work

Bill Gates launched and funded the Alzheimer’s Disease Data Initiative (ADDI) to break research silos and accelerate discovery by pooling datasets and tools; ADDI is frequently cited by Gates and by World Economic Forum reporting as a 2020-era effort to make data more usable across labs and thereby speed progress in diagnostics and therapeutics [1] [4]. Scientific American reports that Gates funds data platforms tied to proteomics and imaging—naming the Global Research and Imaging Platform as an example of an initiative he supports—reflecting a strategy focused on enabling research infrastructure rather than single-drug sponsorship [3].

2. Diagnostics acceleration: sustained commitments to Biomarker and Diagnostics work

Gates has been a major backer of diagnostic-focused funding mechanisms that predate 2020 but continued activity into and beyond that year, notably the Diagnostics Accelerator which had mobilized roughly $100 million in commitments that include Gates among other philanthropists and organizations; the Accelerator’s stated mission is to fast-track blood-based and other noninvasive tests to improve early detection and clinical-trial design [5] [6]. Reporting in 2022 and 2024 underscores Gates’s ongoing interest in blood-based biomarkers and diagnostics as foundational to future therapies [6] [3].

3. Targeted clinical-trial grants: Part the Cloud – Gates partnership

In November (reporting of the partnership), Bill Gates contributed $10 million to the Alzheimer’s Association’s “Part the Cloud” clinical-research programme, bringing that initiative’s clinical investment to a larger total and specifically earmarking support for early-phase trials that target mitochondria/bioenergetics, vascular pathology, protein clearance and neuroinflammation—areas the grant program describes as high priority (Alzheimer’s Association/Europe announcement and the Part the Cloud program page) [7] [8]. The Part the Cloud-Gates grant program also documents joint review procedures involving Gates’ scientific advisers and the Alzheimer’s Association [8].

4. Prize and AI initiatives, and venture-style bets

Press reporting shows Gates backing competitions to harness AI for Alzheimer’s research—examples include a $1 million prize for AI-powered ADRD work—and his broader financial posture includes venture-style investments into diagnostic and therapeutic start-ups through vehicles such as the Dementia Discovery Fund and other private investments (not all of which are Gates Foundation grants) [4] [2] [9]. Forbes and Reuters coverage documents earlier personal investments and ongoing contributions across foundations, venture funds and consortia, although those reports often distinguish personal money from institutional Gates Foundation grants [6] [2].

5. What the sources do not show—and why that matters

Available reporting documents several named projects and commitments—ADDI, Diagnostics Accelerator, Part the Cloud $10 million support, AI prize backing and venture investments—but none of the supplied sources provides an exhaustive list of grants issued specifically by the Bill & Melinda Gates Foundation since 2020 nor a complete accounting separating personal gifts, Gates Ventures activity, and foundation-directed dollars; several articles explicitly note that some funds were personal or came via other collaborators rather than the Gates Foundation itself [2] [6] [3]. Therefore, while the public record confirms Gates’s financial and programmatic involvement in diagnostics, data infrastructure, targeted clinical-trial grant programs and AI/venture funding streams for Alzheimer’s since 2020, it is not possible from these sources alone to produce a definitive, line‑by‑line list of “Gates Foundation” grants in that interval without consulting Gates Foundation grant databases or the recipient organizations’ grant disclosures [7] [8] [5].

Want to dive deeper?
Which Alzheimer’s research grants are listed in the Bill & Melinda Gates Foundation’s public grants database since 2020?
How does the Alzheimer’s Association’s Part the Cloud program select and monitor clinical trial grants in partnership with Bill Gates?
What is the Alzheimer’s Disease Data Initiative (ADDI), who funds it, and what datasets and tools has it released since 2020?